Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial.

doi:10.1038/s41467-026-72985-6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial.

Nature communications - 23 Jul 2026

Christenson Eric S, Wala Jeremiah A, Parkinson Rose, Collins Natalie B, Jakubowski Christopher, Lin Jia-Ren, Qian Kristin, Lu Jiayun, Wang Hao, Ho Won Jin, Chan Sabrina, Kulikowicz Ewa, Klein Rachel, Cetasaan Yvette, Johnson Emma, Berg Maureen, Meyerhardt Jeffrey A, Le Dung T, Schlechter Benjamin L, Browner Ilene, Zheng Lei, Singh Harshabad, Donehower Ross, Jaffee Elizabeth M, Sorger Peter K, Giannakis Marios, Azad Nilofer

Abstract excerpt

PIK3CA is mutated in ~15% of colorectal cancers (CRC). PI3K regulates immunity, inhibition potentially enhances anti-tumor immunity. We launched a phase 1/2 trial of copanlisib (PIK3CA inhibitor) and nivolumab (anti-PD-1) in metastatic microsatellite stable CRC (NCT03711058): Cohort A: PIK3CAwt (n = 17) and Cohort B: PIK3CAmut (n = 22). Copanlisib/nivolumab is well tolerated with recommended phase 2 dose of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Class I Phosphatidylinositol 3-Kinases

Share to Colorectal Neoplasms

Share to Nivolumab

Share to Progression-Free Survival

Share to Pyrimidines

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 42493490
DOI: 10.1038/s41467-026-72985-6
PMCID: PMC13396235

Genes

PIK3CA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Copanlisib in combination with nivolumab formicrosatellite stable colorectal cancer: a phase 1/2 trial.PMID 42493490Read ↗

The Efficacy and Safety of Pembrolizumab, Ipilimumab, and Nivolumab Monoteraphy and Combination for Colorectal Cancer: A Systematic Review and Meta-AnalysisSemantic proximity Read ↗

Panitumumab safety for treating colorectal cancer.Semantic proximity Read ↗

BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA-Mutant Colorectal Cancer.Semantic proximity Read ↗

Nivolumab plus relatlimab in patients with previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the phase II CheckMate 142 studySemantic proximity Read ↗

Colorectal cancer with BRAF V600E mutation: Trends in immune checkpoint inhibitor treatment.Semantic proximity Read ↗

Cell line models for drug discovery in PIK3CA-mutated colorectal cancers.Semantic proximity Read ↗

Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 studySemantic proximity Read ↗

Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.Semantic proximity Read ↗

First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial.Semantic proximity Read ↗

Integration of panitumumab into the treatment of colorectal cancer.Semantic proximity Read ↗

Dual-immunotherapy triumphs: redefining deficient mismatch repair or high microsatellite instability metastatic colorectal cancer first-line treatmentSemantic proximity Read ↗

Pembrolizumab in Asian patients with microsatellite‐instability‐high/mismatch‐repair‐deficient colorectal cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.